Roche Announces Vabysmo’s Long-Term Diabetic Macular Edema Study Data

TOKYO, July 18, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that F. Hoffmann-La Roche Ltd (Head Office: Basel, Switzerland. CEO: Thomas Schinecker) issued a Media Release today, regarding four-year data from the RHONE-X extension study of Vabysmo ® (generic name: faricimab) in diabetic macular edema (DME). Please refer to the link below for details of the Roche’s Media Release: Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study https://www.roche.com/media/releases/med-cor-2024-07-17b

The release as fetched from its publisher. chugai-pharm.co.jp ↗